In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
The Regional Cancer Centre (RCC) at Thiruvananthapuram is a cancer care hospital and research centre. RCC was established in 1981 by the Government of Kerala and the Government of India. It is located in the Thiruvananthapuram Medical College campus in Thiruvananthapuram, the capital city of the state of Kerala. It was established as an expansion of the Radiation Therapy / Radiotherapy department of Medical College Trivandrum. It is a tertiary care center for the managements of all types of cancers. The clinics are mainly on Haematology, Lymphoreticular, soft tissue, bone, head and neck, breast, CNS, gynaecological, urinary, chest, gastro, paediatric oncology and thyroid.
Stephen Michael Hahn is an American physician who served as the Commissioner of Food and Drugs from 2019 to 2021. Before becoming Commissioner, he was an oncologist serving as Chief Medical Executive of the MD Anderson Cancer Center. In 2021 he became Chief medical officer at the venture capital firm that launched Moderna.
The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.
Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.
Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the medical director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons’ laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of “broken immune tolerance” via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons’ clinical team took the biotechnology into the world’s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins.
David B. Agus is an American physician, cancer researcher and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. He is also the author of four books.
Simon J. Hall, M.D., is the Associate Professor and Kyung Hyun Kim, M.D. Chair of Urology and Assistant Professor, Department of Gene and Cell Medicine at The Mount Sinai School of Medicine, as well as the Director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center, both in New York City.
The University of Wisconsin Carbone Cancer Center (UWCCC) is a comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute (NCI), the lead federal agency for cancer research. It is an integral part of both the University of Wisconsin (UW) and the University of Wisconsin Hospital and Clinics. It is located in Madison, Wisconsin.
William K. Oh, is an American medical oncologist, academic and industry leader and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Seattle Cancer Care Alliance (SCCA) is a cancer treatment and research center in Seattle, Washington. Established in 1998, this nonprofit provides clinical oncology care for patients treated at its three partner organizations: Fred Hutchinson Cancer Research Center, Seattle Children's and UW Medicine. Together, these four institutions form the Fred Hutch/University of Washington Cancer Consortium.
Walter "Wally" J. Curran, Jr. is an American radiation oncologist specializing in the treatment of malignant brain tumors and locally advanced lung cancer.
Lorenzo Cohen is a professor in the Department of General Oncology and Behavioral Science and the director of the Integrative Medicine Program at the University of Texas MD Anderson Cancer Center. He is also a distinguished clinical professor at the Fudan University Shanghai Cancer Center in Shanghai, China. Cohen is a founding member and past president of the Society for Integrative Oncology.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Robert Maki is an American medical oncologist, Professor of Medicine at the Hospital of the University of Pennsylvania, He is a specialist in the management of and translational research regarding sarcoma, the group of connective tissue malignancies that include leiomyosarcoma, gastrointestinal stromal tumor (GIST), liposarcoma, angiosarcoma, Ewing sarcoma, desmoid tumor and many others.
Oliver Sartor is an American oncologist and research scientist. He is currently the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology.
Fred Joseph Ansfield, M.D. was an American pioneer of medical oncology. He was a leader in applying 5-FU (5-Fluorouracil) to humans, demonstrating its effectiveness as a chemotherapy drug. Ansfield co-founded the American Society of Clinical Oncology (ASCO) in 1964, along with Harry Bisel, Arnoldus Goudsmit, Herman H. Freckman, Robert W. Talley, William Wilson and Jane Cooke Wright. He served as ASCO's third president (1966-1967).
Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.
